Hepatocellular Carcinoma Market

Market Overview:

The hepatocellular carcinoma market reached a value of USD 830 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 1,650 Million by 2035, exhibiting a growth rate (CAGR) of 6.49% during 2025-2035.

The hepatocellular carcinoma market has been comprehensively analyzed in IMARC's new report titled "Hepatocellular Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Hepatocellular carcinoma (HCC) is a type of oncological disease that arises from the hepatocytes or liver cells. It is a severe illness that can destroy hepatic cells and interfere with the liver's ability to function, causing life-threatening complications. The symptoms of the ailment vary depending on the stage and size of the tumor, and many people may not experience any indications at all. Some of the non-specific symptoms include abdominal pain, nausea, vomiting, tiredness, etc. Individuals suffering from hepatocellular carcinoma may also experience yellow skin, loss of appetite, abdominal swelling, unintentional weight loss, easy bruising, etc. The diagnosis of this ailment is typically based on the patient's symptoms, blood testing, and imaging evaluation. The healthcare provider may also perform numerous diagnostic procedures, such as multi-phase computerized tomography scans and contrast-enhanced magnetic resonance imaging, to detect disease staging among patients. Additionally, a biopsy or ultrasound of the tumor is required to confirm the diagnosis of hepatocellular carcinoma.

The increasing incidences of chronic hepatitis B and C infections, which cause long-term liver inflammation and lead to the development of cirrhosis, are primarily driving the hepatocellular carcinoma market. In addition to this, the rising prevalence of several associated risk factors, including excessive alcohol consumption, obesity, diabetes, accumulation of fat in the liver, etc., is also bolstering the market growth. Furthermore, the widespread adoption of monoclonal antibodies for treating unresectable or advanced disease conditions is acting as another significant growth-inducing factor. This medication can prevent the proliferation of unhealthy cells, thereby reducing tumors' ability to grow and metastasize. Additionally, the escalating demand for locoregional therapies, such as thermal ablation and transarterial chemoembolization, that aim to decrease tumor viability, delay disease progression, and ultimately extend overall survival is also creating a positive outlook for the market. Moreover, the inflating utilization of selective internal radiation therapy, which potently delivers millions of tiny radioactive beads directly to liver tumors and provides cancer irradiation, is further augmenting the market growth. Apart from this, the emerging popularity of percutaneous ethanol injection among patients with early-stage HCC who are not candidates for surgery or other more invasive treatments is expected to drive the hepatocellular carcinoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the hepatocellular carcinoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for hepatocellular carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hepatocellular carcinoma market in any manner.

Key Highlights:

• Hepatocellular carcinoma is diagnosed in around 900,000 people globally each year.
• It is the fifth most prevalent malignancy in men (69.8% of all hepatocellular carcinoma cases) and the ninth among women.
• According to the Global Cancer Observatory (GCO), Asia accounts for 72.5% of all HCC cases, with 11.6 new cases per 100,000 population.
• HCC is less prevalent in the US and Europe, with 5.2 new cases per 100,000 people per year.
• About 830,000 individuals die from HCC annually, making it the third most common cause of cancer-related deaths worldwide.
• The Surveillance, Epidemiology, and End Results (SEER) Program indicated a 20.3% 5-year relative survival rate for individuals diagnosed with HCC.

Drugs:

Keytruda (Pembrolizumab) is an anti-programmed death receptor-1 (PD-1) medication that enhances the immune system's ability to detect and attack tumor cells. Keytruda is a humanized monoclonal antibody that inhibits the interaction of PD-1 and its ligands, PD-L1 and PD-L2, activating T lymphocytes that can affect both tumor and healthy cells.

TTI-101 is under clinical development by Tvardi Therapeutics for metastatic hepatocellular carcinoma. It is an oral small molecule STAT3 inhibitor. STAT3 is a regulatory molecule that contributes considerably to hepatocellular carcinoma progression.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the hepatocellular carcinoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the hepatocellular carcinoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current hepatocellular carcinoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the hepatocellular carcinoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the hepatocellular carcinoma across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the hepatocellular carcinoma across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of incident cases (2019-2035) of hepatocellular carcinoma across the seven major markets?
• What is the number of incident cases (2019-2035) of hepatocellular carcinoma by age across the seven major markets?
• What is the number of incident cases (2019-2035) of hepatocellular carcinoma by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with hepatocellular carcinoma across the seven major markets?
• What is the size of the hepatocellular carcinoma patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend hepatocellular carcinoma of?
• What will be the growth rate of patients across the seven major markets?

Hepatocellular Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for hepatocellular carcinoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hepatocellular carcinoma market?
• What are the key regulatory events related to the hepatocellular carcinoma market?
• What is the structure of clinical trial landscape by status related to the hepatocellular carcinoma market?
• What is the structure of clinical trial landscape by phase related to the hepatocellular carcinoma market?
• What is the structure of clinical trial landscape by route of administration related to the hepatocellular carcinoma market?